Cetera Investment Advisers
TGTX icon

Cetera Investment Advisers’s TG Therapeutics TGTX Stock Holding History

Cetera Investment Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$20.8K – 2299
2023
Q1 		$20.8K Sell
2,000
-500
-20% -$7.59K ﹤0.01% 2122
2022
Q4 		$16.1K Buy
+2,500
New +$18.1K ﹤0.01% 2067

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cetera Investment Advisers's TGTX Position: Q1 2026 in Review

Cetera Investment Advisers reduced its TG Therapeutics (TGTX) stake by 7.6% in Q1 2026, selling an estimated $174K and leaving 70,530 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

Cetera Investment Advisers first reported a position in TGTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.51M in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Cetera Investment Advisers held 70,530 shares of TG Therapeutics worth $2.34M as of Q1 2026.
  • Cetera Investment Advisers sold 5,834 TG Therapeutics shares in Q1 2026, an estimated $174K.
  • TG Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #2149 holding.
  • Cetera Investment Advisers first reported a position in TG Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Cetera Investment Advisers's TG Therapeutics position peaked at $2.51M in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.